NKTR (Nektar Therapeutics) ROCE % : -47.16% (As of Sep. 2024)

View and export this data going back to 1994. Start your Free Trial

What is Nektar Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Nektar Therapeutics's annualized ROCE % for the quarter that ended in Sep. 2024 was -47.16%.

Nektar Therapeutics ROCE % Historical Data

The historical data trend for Nektar Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nektar Therapeutics ROCE % Chart

Nektar Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-21.33

-26.71

-38.78

-40.14

-50.73

Nektar Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-38.37	-38.26	-36.28	-58.33	-47.16

Nektar Therapeutics ROCE % Calculation

Nektar Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-250.922	/	( ( (710.6 - 68.204)	+	(398.033 - 51.269) )	/ 2 )
	=	-250.922	/	( (642.396	+	346.764)	/ 2 )
	=	-250.922	/	494.58
	=	-50.73 %

Nektar Therapeutics's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-124.112	/	( ( (343.334 - 57.326)	+	(307.966 - 67.583) )	/ 2 )
	=	-124.112	/	( ( 286.008	+	240.383 )	/ 2 )
	=	-124.112	/	263.1955
	=	-47.16 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Nektar Therapeutics (NAS:NKTR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Nektar Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Nektar Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nektar Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (NAS:NKTR) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

0UNL:UK ITH:Germany ITH:Germany

Address

455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158

Website

https://www.nektar.com

Nektar Therapeutics is a pharmaceutical company focused on the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. The company is focused on discovering and developing medicines in the field of immunotherapy. Its clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases (e.g. rezpegaldesleukin and NKTR-0165, respectively) and cancer (e.g. NKTR-255).

Executives

Howard W Robin	director, officer: President & CEO
Jonathan Zalevsky	officer: Chief R&D Officer	455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158
Mark Andrew Wilson	officer: SVP & General Counsel	1613 RAY DRIVE, BURLINGAME CA 94010
Robert Chess	director, officer: Executive Chairman
Myriam Curet	director	1020 KIFER ROAD, SUNNYVALE CA 94086
Jeffrey Robert Ajer	director	C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Sandra A. Gardiner	officer: Chief Financial Officer	CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Jillian B. Thomsen	officer: VP & Chief Accounting Officer	C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Karin Eastham	director	C/O BURNHAM INSTITUTE FOR MEDICAL RESEAR, 10901 N. TORREY PINES ROAD, LA JOLLA CA 92037
Gil M Labrucherie	officer: SVP, COO & CFO	150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
John Northcott	officer: SVP & Chief Commercial Officer	455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158
Diana Brainard	director	C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
R Scott Greer	director	6207 E. INDIAN BEND RD, PARADISE VALLEY AZ 85253
Lutz Lingnau	director	15 INDIAN HOLLOW ROAD, MENDHAM NJ 07945
Stephen K Doberstein	officer: Chief Scientific Officer	129 ELSIE STREET, SAN FRANCISCO CA 94110